Thanks Jay for the information about the AAP's "New Mother's Guide to
Breast-Feeding." which will be distributed by Ross Labs with their name and
logo.  I thought I would dedicate this post to Ross/Abbott for their
"support" of breastfeeding.  Although support isn't quite the word I'd use.
Here's one of their many patents for infant formula based on human milk.  You
might want to read and reread the sentence where this particular ingredient
can be obtained from human milk.  Of course, they wouldn't dare use real
human milk in their infant formula--No guess not, just something genetically
engineered....
Valerie W. McClain, IBCLC

PS  Who thinks instead of writing the AAP, that we ought to write to
Ross/Abbott--why not send them lots of e-mail......

http://www.uspto.gov/patft/index.html
patent # 6083934
"Nutritional Formulations containing lacto-N-neotetraose."
inventor:  Prieto, et al.
assignee:  Abbott

"The infant formula can be sterilized and subsequently utilized on a
ready-to-feed (RTF) basis or stored in a concentrated liquid or a powder. The
powder can be prepared by spray drying the infant formula prepared as
indicated above, and the formula can be reconstituted by rehydrating the
concentrate. Infant nutritional formulas are well known in the art and
commercially available (e.g., Similac.RTM. and Alimentum.RTM. from Ross
Products Division, Abbott Laboratories).

The formulations of the present invention contain an amount of LNnT effective
to stimulate the growth and/or metabolic activity of bacteria of the genus
Bifidobacterium. Several strains of Bifidobacterium have been described in
the gut of humans, particularly infants, as discussed earlier. Those strains
include Bifidobacterium infantitis (B. infantitis), Bifidobacterium breve (B.
breve), Bifidobacterium bifidum (B. Bifidum), and Bifidobacterium
adolescentis (B. adolescentis).

LNnT can be isolated in any manner known per se from pooled human milk or
produced by chemical synthesis. For example, LNnT can be synthesized
chemically by enzymatic transfer of saccharide units from donor moieties to
acceptor moieties using glycosyltransferases as described in U.S. Pat. No.
5,288,637 and WO96/10086, herein incorporated by reference. The preferred
method for synthesizing LNnT involves the enzymatic transfer of saccharide
units from saccharide-nucleotides to saccharide acceptors using
glycosyltransferases where the saccharide-nucleotides and
glycosyltransferases used are in an unpurified form. This preferred method is
described in "A Process for Synthesizing Oligosaccharides" filed concurrently
with this application. Additionally, the LNnT used in the nutritional
formulation of the present invention should be in purified or partially
purified form and free of bacterial toxins, viruses and other harmful
contaminants.

Actual dosage levels of LNnT in the formulations of the present invention may
be varied so as to obtain an amount of active ingredient that is effective to
obtain a desired response for a particular composition and method of
administration. The selected dosage level therefore depends upon the desired
therapeutic or nutritional effect, on the route of administration, and on the
desired duration of administration and other factors.

In a preferred embodiment, an amount of LNnT effective to simulate
Bifidobacteria growth and/or metabolism is from about 0.05 to about 2.0 mg/ml
of nutritional formulation. More preferably, an effective amount of LNnT is
from about 0.075 to about 1.0 mg/ml and, most preferably from about 0.1 to
about 0.5 mg/ml. Growth stimulation of the Bifidobacterium is determined as
an increase in the biomass of the bacteria as determined by increases in
optical density (O.D.) measurements and/or increase in the number of
bacteria. The metabolism of the Bifidobacterium is considered to be
stimulated when the enzymatic activity per bacterial cell increases.
Preferably this metabolic stimulation is measured using enzymes from the
bacteria which are constitutively active or are induced to be active prior to
any measurements of metabolic stimulation (Sambrook, J., et al., Molecular
Cloning A Laboratory Manual, 2d Edition, Cold Spring Harbor Laboratory Press
(1989)). "


             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html